5 Key Takeaways

• 1

  EULAR updated its Behçet’s syndrome management recommendations, emphasizing earlier biologic use for severe organ involvement.

• 2

  Colchicine remains the first-line treatment for mucocutaneous involvement, with alternatives like apremilast for refractory cases.

• 3

  For Behçet’s uveitis, immunosuppressive treatment is essential, with infliximab preferred for sight-threatening inflammation.

• 4

  The task force recommends high-dose glucocorticoids plus infliximab for arterial involvement, reflecting new evidence supporting this approach.

• 5

  The recommendations highlight the need for individualized treatment and multidisciplinary care to maximize patient quality of life.